Merrimack (Nasdaq: MACK) shares are down over 21 percent with heavy volume Thursday afternoon after the company announced that ONIVYDE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Momentum Movers Trader Talk

Merrimack Pharmaceuticals (MACK) Weakness Creates Buying Opportunity, Mizuho Securities SaysOctober 23, 2015 6:51 AM Merrimack Pharma (MACK) to Resume Trading at 1:40 PM EDTOctober 22, 2015 1:32 PM Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic CancerOctober 22, 2015 1:11 PM FDA Approves Merrimack Pharma's (MACK) ONIVYDEOctober 22, 2015 11:32 AM Merrimack Pharma (MACK) Halted, News PendingOctober 22, 2015 11:23 AM PharmaEngine Announces Taiwan FDA Approval of ONIVYDE to Treat Metastatic Pancreatic Cancer (MACK)October 22, 2015 9:08 AM PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic CancerOctober 22, 2015 9:05 AM